RUDDY RAYMOND B
Known title: DirectorCIK: 0001054997
RUDDY RAYMOND B's purchase track record
How the stock did after each of RUDDY RAYMOND B's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
4
of 4 since June 14, 2022
Stock higher 6 months later
100%
3 months: 75%
Median 6-month return
+23.7%
3 months: +10.0%
Beat the S&P 500
100%
median +13.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/16/2025 | MMS | $100K | +27.1% | +25.5% | +13.0% |
| 12/12/2024 | MMS | $249K | -5.1% | +1.2% | -0.1% |
| 12/7/2022 | MMS | $401K | +14.4% | +21.9% | +8.5% |
| 6/14/2022 | MMS | $1.00M | +5.6% | +27.8% | +7.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| MMS | ▲ Buy | Grant | 694 | $0 | 12/1/2025 | View on chart |
| MMS | ▲ Buy | Grant | 685 | $0 | 8/31/2025 | View on chart |
| MMS | ▲ Buy | Open Market | 1,435 | $100K | 6/16/2025 | View on chart |
| MMS | ▲ Buy | Grant | 827 | $0 | 5/31/2025 | View on chart |
| MMS | ▲ Buy | Open Market | 3,490 | $249K | 12/12/2024 | View on chart |
| MMS | ▲ Buy | Open Market | 5,730 | $401K | 12/7/2022 | View on chart |
| MMS | ▼ Sell | Gift | 5,730 | $0 | 12/6/2022 | View on chart |
| MMS | ▲ Buy | Open Market | 17,341 | $1.0M | 6/14/2022 | View on chart |
| MMS | ▼ Sell | Gift | 9,500 | $0 | 12/20/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Maximus Shifts Earnings Focus to Defense and Medicaid
Maximus is moving its earnings mix away from VA incentives toward defense and Medicaid contracts, as discussed in a recent Yahoo article. A ChartMill piece highlighted the company’s strong cash flow and low valuation. The Q3 2026 earnings call transcript provides further detail on the company’s strategy. These developments give insight into Maximus’s future revenue mix.
Maximus Shifts Earnings Focus to Defense and Medicaid. Maximus is moving its earnings mix away from VA incentives toward defense and Medicaid contracts, as discussed in a recent Yahoo article. A ChartMill piece highlighted the company’s strong cash flow and low valuation. The Q3 2026 earnings call transcript provides further detail on the company’s strategy. These developments give insight into Maximus’s future revenue mix.